490 BIOTECH INC
Knoxville, TN · Biotech · Private
Autonomously bioluminescent induced pluripotent stem cells (iPSCs) expressing synthetic luciferase/luciferin for real-time toxicological screening assays
490biotech.com →- Grants
- $9.4M
- 21 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 5
- 1 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2014201520162017201820192020
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Agriculture · An Improved Bioassay For The Surveillance Of Dioxins In The U.S. Food Supply | $99,551 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows | $149,051 | |
| Federal grant | Department of Health and Human Services · Phase I · Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows | $149,051 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Expressing humanized bacterial luciferase in stem cells: Moving beyond firefly luciferase to expand the informational capacity of animal models for regenerative medicine | $149,960 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicals | $538,007 | |
| Federal grant | Department of Health and Human Services · Phase II · Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicals | $995,753 | |
| Federal grant | Department of Health and Human Services · Phase I · Expressing humanized bacterial luciferase in stem cells: Moving beyond firefly luciferase to expand the informational capacity of animal models for regenerative medicine | $149,960 | |
| Federal grant | Department of Health and Human Services · Phase I · Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $224,924 | |
| Federal grant | Department of Health and Human Services · Phase I · Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $224,924 | |
| Federal grant | Department of Health and Human Services · Phase II · Expressing bacterial bioluminescence in human cell lines: Engineering autobioluminescent reporter cells to screen for endocrine disruptor chemicals | $457,746 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine | $993,957 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine | $496,198 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows | $522,620 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows | $996,512 | |
| Federal grant | Department of Health and Human Services · Phase I · Autonomously-activating bioluminescent reporters to enable continuous, real-time, non-invasive brain cell imaging | $150,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Autonomously-activating bioluminescent reporters to enable continuous, real-time, non-invasive brain cell imaging | $150,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Development of a high-throughput screen to detect the effects of both pre- and post-biotransformed compounds for enhanced content drug discovery workflows | $473,892 | |
| Federal grant | Department of Health and Human Services · Phase II · Expressing humanized bacterial luciferase in stem cells: Moving beyond fireflyluciferase to expand the informational capacity of animal models for regenerativemedicine | $497,759 | |
| Federal grant | Department of Health and Human Services · Phase II · Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $499,634 | |
| Federal grant | Department of Health and Human Services · Phase II · Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $991,009 | |
| Federal grant | Department of Health and Human Services · Phase II · Expanding the throughput of real-time toxicological screening of cardiac differentiation by expressing a synthetic luciferase/luciferin genetic pathway in iPSCs | $491,375 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3063 | Entrega | — | — |
| 3064 | Nested Therapeutics | — | — |
| 3065 | ELSOHLY LABORATORIES, INC. | — | — |
| 3066 | 490 BIOTECH INC | — | — |
| 3067 | Synthis Therapeutics, Inc. | — | — |
| 3068 | Ottimo Pharma | — | — |
| 3069 | Vidasym, Inc | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- System Of Stable Gene Expression In Cell Lines And Methods Of Making And Using The Sameapplication
- Lux Expression In Cells And Methods Of Useapplication
- Lux Expression In Cells And Methods Of Usegranted
- Lux Expression In Cells And Methods Of Useapplication
- Lux Expression In Cells And Methods Of Useapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.